Navigation Links
CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
Date:12/8/2008

g regimen containing nitrosourea and procarbazine, and for the treatment of newly diagnosed GBM concomitantly with radiotherapy and then as maintenance treatment.

About Malignant Gliomas

The worldwide incidence rate of primary malignant brain and central nervous system tumors, using the world standard population, is 3.7 per 100,000 person in males and 2.6 per 100,000 person in females(1). The most common type of primary malignant brain tumors are gliomas, with AA and GBM being the most common and among the most serious types.

Important Information Regarding EU Labeling for TEMODAL

Full prescribing information for TEMODAL can be found at http://www.emea.europa.eu/humandocs/Humans/EPAR/temodal/temodal.htm

Important Information Regarding US Labeling for TEMODAR

TEMODAR Capsules are contraindicated in patients who have a history of hypersensitivity to any of its components, or to DTIC.

Patients treated with TEMODAR Capsules may experience myelosuppression including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medications associated with aplastic anemia including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim complicates assessment. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression. Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have also been observed.

TEMODAR may cause fetal harm when administered to a pregnant woman. Nursing should be discontinued in women taking TEMODAR.

Prophylaxis against Pneumocystis carinii pneumonia is required for all patients receiving
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
2. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
5. Task Force Recommends Screening for Hearing Loss in All Newborns
6. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
7. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... The Assistance Fund announces the addition of ... assistance for copay to individuals diagnosed with Melanoma. ... of the Melanoma Copay Assistance Program to our portfolio ... director. "With each additional program we are closer to ... no one is denied access to medications due to ...
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... approval of Zarxio (filgrastim-sndz) -- the first biosimilar ... -- points toward growth in the ... Information. The mainstream CMO industry is geared to ... infrastructure to produce major biopharmaceutical products. The healthcare ...
(Date:5/22/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has announced ... Application Dossiers for Oversea Medical device registration and ... to their offering. The Chinese medical ... the most growth potentiality, which is attracting more ... to penetrate such market. It is estimated that ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... Corporation (Nasdaq: DNDN ) today announced that ... Phase 1 clinical trial of D3263 in patients with ... drug candidate designed to target TRPM8 (a transmembrane cation ... The trial is an open-label, dose-escalation study evaluating ...
... strategies for personalized approach to cancer treatmentSEATTLE, April ... subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and ... which utilized RNA interference (RNAi) and bioinformatics to ... that enhance the anti-tumor response to the experimental ...
Cached Medicine Technology:Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 2Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
(Date:5/25/2015)... World Patent Marketing, a vertically integrated ... Little Party Table, a party invention that gives people ... suit their party needs. , "Worldwide indoor and outdoor ... past year. Party Supply Rentals alone are a ... CEO and Creative Director of World Patent Marketing ...
(Date:5/25/2015)... Iowa City, Iowa (PRWEB) May 25, 2015 ... Engineering Excellence awards for design of the ... in Iowa City, Iowa.    The project received a National Recognition ... and an Honor Award from ACEC – Iowa. ... outstanding engineering achievements. , The $50.2 million expansion is ...
(Date:5/25/2015)... Tunstall Americas announces major investment in new technology ... to its Medical Answering Service customers. Through a ... Tunstall now provides a seamless transition between a health ... ensure superior patient satisfaction. , Tunstall is ... million in expanded facilities and the latest telecommunication software ...
(Date:5/24/2015)... Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... patients for concerns about hair loss. Although it is ... clear that there are environmental factors such as metabolism, ... can contribute. Since they offer a comprehensive approach to ... peri and post-menopausal woman, they can help patients find ...
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
Breaking Medicine News(10 mins):Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... health insurance providers can motivate and sustain member participation in wellness ... ... Louis, MO (PRWEB) November 6, 2008 -- As a strategic partner ... new whitepaper for health insurance companies that need to improve wellness ...
... Long-Lasting Results and Physician Expertise Most Important, ... A new study,conducted by the American Society ... business of sanofi-aventis U.S. LLC, reveals the,influencers ... medical,anti-aging treatments. The study surveyed women ages ...
... 6 Continuing its efforts to,educate, inform, and ... a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... on,Monday, November 10, 2008 at 6:00 PM on ... frank discussion with Joy Loverde, a,nationally known expert ...
... and Healthier for People With,Diabetes and Their Caregivers, ... a time,for love, laughter, and family, usually accompanied by ... temptations may leave some,of the nearly 24 million people ... Last holiday season, dLife helped over 100,000 online,visitors survive ...
... Corporation,(Nasdaq: RGEN ) today reported results for the ... Total revenue for the quarter was,$5,090,000 compared to total ... 2008 ended September 30, 2007. Total revenue was comprised,of ... of Protein A revenue, for the second quarter of ...
... Corporation,(Nasdaq: RGEN ) announced today that the ... evaluate the use of RG2417, an oral formulation ... 2b study is a,multi-center, randomized, double-blind, placebo-controlled clinical ... will receive,either RG2417 or placebo twice daily for ...
Cached Medicine News:Health News:Health and Wellness Incentives 2Health News:New Study Reveals What Women Want When Considering Cosmetic Procedures 2Health News:Health Caring for the Elderly 2Health News:Back By Popular Demand - dLife Holiday Helpline 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 7Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 8Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4
Integrate RFID and bar code technology with the new DR1000 Dual RFID/Bar Code Reader by Precision Dynamics Corporation (PDC). It provides an easy migration from bar codes to RFID tags for healthcare ...
... only task-critical information to the operator ... Up to 14 additional computers can ... the facility using a dedicated local ... and administrators can all access the ...
... VerdaSee Patient Bracelet-ID™ provides a solution ... personnel to elopement or unauthorized movement ... issues are a key concern. Certain ... care, Alzheimer's victims, patients with highly ...
... a small radio transmitter combines state-of-the-art ... design. The tag incorporates a tamper ... as the tag is attached to ... electronic Heartbeat® signal every 10 seconds ...
Medicine Products: